Evidence map›Paper›PMID 40761788›Full record

ArticleFrontiers in immunology2025

Patients with peripheral artery disease demonstrate altered expression of soluble and membrane-bound immune checkpoints.

Rosanne D Reitsema, Seta Kurt, Ignacio Rangel, Hans Hjelmqvist, Mats Dreifaldt, Allan Sirsjö, Ashok Kumar Kumawat

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. TIM-3 in Cardiovascular Disease.Current heart failure reports · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rosanne D ReitsemaFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Seta KurtFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Ignacio RangelFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Hans HjelmqvistFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Mats DreifaldtDepartment of Cardiothoracic Surgery, Örebro University Hospital and University Health Care Research Centre, Örebro, Sweden.
Allan SirsjöFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Ashok Kumar KumawatFaculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Studies suggest that immune checkpoints play a role in accelerating the formation of atherosclerosis. We aimed to assess the expression of soluble and membrane-bound immune checkpoints in patients with peripheral artery disease (PAD). Methods: The levels of 14 soluble immune checkpoints were assessed in blood plasma of PAD patients (n= 37) and healthy controls (HCs, n=39) by Multiplex protein assay. The surface expression of immune checkpoints on peripheral blood immune cells was determined by flow cytometry. Cytokine production capacity was measured by flow cytometry in TIM-3+ T cells to determine immune exhaustion. Results: Soluble levels of PD-L2 were decreased in female PAD patients, whereas soluble levels of TIM-3 showed a trend towards an increased concentration in female PAD patients. PD-L2+ frequencies were higher within all monocyte subsets in PAD patients. CD4+ T cells from PAD patients had increased frequencies of TIM-3+ cells, showing little overlap with other immune exhaustion markers. TIM-3+ CD4+ T cells from both PAD patients and HCs, had a low capacity to produce pro-inflammatory cytokines, but a higher capacity to produce IL-10 compared to TIM-3- CD4+ T cells. Conclusion: PAD patients show differences in the expression of membrane-bound and soluble immune checkpoints. Some of these differences might be caused by prolonged immune activation, although immune exhaustion markers did not always overlap.

Indexed as

Immune Checkpoint ProteinsPeripheral Arterial DiseaseAgedBiomarkersCD4-Positive T-LymphocytesCytokinesFemaleHepatitis A Virus Cellular Receptor 2HumansMaleMiddle AgedBiomarkersCytokinesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Immune Checkpoint Proteinsantigen presenting cellsimmune checkpointsintermittent claudicationperipheral artery diseaseT cells

Identifiers

PMID40761788
PMCPMC12318762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.